50 likes | 162 Views
Monday Pre-Meeting. About ½ of this seminar’s participants met this afternoon in what turned out to b and ad-hoc, informal brainstorming session
E N D
Monday Pre-Meeting • About ½ of this seminar’s participants met this afternoon in what turned out to b and ad-hoc, informal brainstorming session • Key outcome: we need to come out of these three days with a 1-2 campaigns with global/regional and national components; some way to coordinate this work and; support and finance it • Two main campaign suggestions: on FTAs and Global Fund • There is a plan by MSF to hold an A2M strategy meeting in January/February with a larger group; this must be a follow-up to our meeting this week in Bangkok
Action Items: Short Term and Long Term • Short Term • Free Trade Agreements • Barriers to further scale up of treatment • Collapse of key institutions in global response to AIDS and other diseases • Need to widen scope of A2M movement and partners • Long Term • Need for reforms in TRIPS agreement • Need a new global framework on right to health integrating IP • Need to address consolidation in pharmaceutical industry • Need to address models of innovation and ownership of knowledge • Need to address technology transfer issues in drug and diagnostics manufacture
Critical Short Term Issues • Free Trade Agreements • USA/Asia-Pacific • EU/Asia • EU/Africa • EU/Mercosur • ACTA (counterfeit) • Collapse of Health Institutions • Global Fund cancellation of Round 11—need for US$2B in 200 days • Need for major reforms within Global Fund • Re-focus activities on A2M/treatment • Address overhead/waste • Explore re-programming of existing funds • Need to address centralized, privatized procurement of drugs (e.g. Clinton, UNITAID, PEPFAR) • Need to address effect of Global Fund set-backs on marginalized populations at national level • WHO privatization (esp. Essential Drugs Department)
Critical Short Term Issues • Widening the Movement • Need to address NCDs • Targets and commitments by WHO • Need to address HCV/HBV/TB • Need to engage broader health movements • Need to engage other partners key to work on FTAs etc. (e.g. food security groups, Swedish Pirate Party, Occupy Wall St.) • Need to develop grassroots approach to IP/trade/access literacy • Need to outreach to trade ministries • Scale Up of Treatment • Encourage LDCS to extend deadline beyond 2016 • Reach out systematically to generic and API producers (esp. in China, Eastern Europe, etc) • Streamline drug pre-qualification and other quality assessment mechanisms • Bring back a discussion of industrial policy to foster local generic production • Quietly support Chinese CL on TDF • Ensure greater, independent oversight of treatment guideliens development
Potential Campaign Strategies: FTAs • Lobbying US Congress and White House • Demonstrations at US/EU embassies and consulates • Demonstration at International AIDS Conference • Targeting current negotiations happening from January-March (e.g. Australia) • Developing alternative text for trade agreements • Outreach to trade ministers • Developing new “sexy” media strategy • Developing new social media strategy • Missing the Target Report on IP Barriers to ART Access